CDK7 and acute myeloid leukemia: SY-1365 (a THZ1 derivative), a selective inhibitor of CDK7 under clinical trials in breast and ovarian cancers, preferentially decreased the expression of SE-related oncogenic genes with very little influence on housekeeping genes in acute myeloid leukemia (AML) cells [105].